Senior Novartis Exec Joins Proteus Digital Health as CFO

Proteus Digital Health announced that Uneek Mehra has joined the company as chief financial officer. Mr. Mehra has more than twenty years of global finance experience and was previously a senior leader in finance at Novartis, one of the world’s largest global pharmaceutical companies. He has managed substantial P&Ls and through his experience is well-positioned to help Proteus realize its capital markets ambitions.
 
“R&D productivity in pharma—the key to industry viability—has been halving every 7 years for 5 decades. Joining Proteus on the cusp of defining a new therapeutic category that integrates silicon and software into the pharmaceutical industry’s products and innovation tool kit is a tremendous opportunity to reverse that trend. I am delighted to join the company as chief financial officer,” said Uneek Mehra. “Now is the perfect time for Proteus to accelerate its leadership position in the development and commercialization of Digital Medicines.”
 
As chief financial officer Mr. Mehra will lead the Finance, IT, People, and Facilities teams. He will be a key driver of growth as Proteus expands its commercial footprint in the US and Asia, both directly and through partnerships with pharmaceutical companies.
 
Mr. Mehra has deep experience across pharmaceuticals, technology and financial services, through senior roles at Novartis, IBM and Citibank. At Novartis, he had responsibilities in corporate finance, commercial finance, corporate business development and treasury across the U.S., Switzerland, and China. His pharmaceutical business exposure includes primary care, specialty care, and oncology. These businesses included products across the entire industry lifecycle from early research to established medicines.
 
Proteus co-founder and CEO Andrew Thompson said, “Uneek Mehra brings extensive industry acumen to Proteus. For more than a decade he has observed that solving the problem of patient adherence to medication, and enabling doctors to more effectively prescribe the right drug to the right patient at the right time, is a market opportunity worth billions.”